CN103907661A - Health care biscuit capable of preventing hyperglycemia - Google Patents
Health care biscuit capable of preventing hyperglycemia Download PDFInfo
- Publication number
- CN103907661A CN103907661A CN201410179957.7A CN201410179957A CN103907661A CN 103907661 A CN103907661 A CN 103907661A CN 201410179957 A CN201410179957 A CN 201410179957A CN 103907661 A CN103907661 A CN 103907661A
- Authority
- CN
- China
- Prior art keywords
- health care
- lycopodium calvatum
- liquid extract
- parts
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015895 biscuits Nutrition 0.000 title claims abstract description 24
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 24
- 230000036541 health Effects 0.000 title abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 15
- 235000014121 butter Nutrition 0.000 claims abstract description 9
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 9
- 241000195947 Lycopodium Species 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 21
- 244000197580 Poria cocos Species 0.000 claims description 11
- 235000008599 Poria cocos Nutrition 0.000 claims description 11
- 241000110637 Cuscuta chinensis Species 0.000 claims description 10
- 240000002948 Ophiopogon intermedius Species 0.000 claims description 10
- 244000215777 Plumeria rubra Species 0.000 claims description 10
- 235000013087 Plumeria rubra Nutrition 0.000 claims description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 8
- 235000010447 xylitol Nutrition 0.000 claims description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 8
- 229960002675 xylitol Drugs 0.000 claims description 8
- 239000000811 xylitol Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 abstract description 27
- 239000008280 blood Substances 0.000 abstract description 27
- 235000009508 confectionery Nutrition 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 7
- 235000013312 flour Nutrition 0.000 abstract description 5
- 210000003205 muscle Anatomy 0.000 abstract description 4
- 239000012530 fluid Substances 0.000 abstract description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 2
- 208000026435 phlegm Diseases 0.000 abstract description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 1
- 241000195954 Lycopodium clavatum Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000002040 relaxant effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 26
- 239000003814 drug Substances 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 6
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229960004580 glibenclamide Drugs 0.000 description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 240000004153 Hibiscus sabdariffa Species 0.000 description 2
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000009361 ascariasis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000016253 exhaustion Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a health care biscuit capable of preventing hyperglycemia. The health care biscuit capable of preventing hyperglycemia is composed of, by weight, 20 parts of lycopodium clavatum fluid extract, 120 parts of cake flour, 10 parts of skim milk powder, 40 parts of butter and 25 parts of newtol. The health care biscuit capable of preventing hyperglycemia is sweet and fresh in taste, and a new taste of the health care biscuit is added; the health care biscuit capable of preventing hyperglycemia has the functions of relaxing the muscles and activating blood, clearing phlegm and damp obstruction and reducing blood sugar level and being applicable to preventing and controlling hyperglycemia.
Description
Technical field
The present invention relates to a kind of health-caring biscuit, especially a kind of health-caring biscuit of preventing and treating hyperglycaemia.
Background technology
Hyperphagia sweet food or Sugared beverages cause one of reason of hyperglycaemia.Under normal circumstances, human body can be regulated with this two large regulating system of nerve regulation and be guaranteed that the source of blood sugar and outlet keep balance, make blood sugar maintain certain level by hormone.But under the acting in conjunction of inherent cause (as diabetes family history) and environmental factor (as irrational meals, obesity etc.), two large regulatory functions get muddled, and just there will be the rising of blood sugar level.Long-term hyperglycaemia can make each histoorgan generation pathology of whole body, causes the generation of acute and chronic complication.As pancreas function exhaustion, dehydration, electrolyte disturbance, nutritional deficiency, resistance decline, impaired renal function, DPN, eyeground pathological changes etc.Controlling hyperglycaemia becomes the important topic of people's daily health caring.
Diabetes are mainly that the five internal organs are weak due to the plain body deficiency of Yin in the traditional Chinese medical science, multiple because of eating and drinking without temperance, overfeeding delicious food, and disorder of emotion, labor is wanted excessively, and causes deficiency of kidney-YIN, and lung stomach is scorching; Interpretation of the cause, onset and process of an illness emphasis is that the deficiency of Yin is scorching, and taking the deficiency of Yin as this, scorching is mark; With the passing of time disease prolongs, yin deficiency affecting yang, deficiency in both YIN and YANG; The deficiency of Yin is scorching, and the bright liquid in consumption Tianjin makes blood viscous, the not smooth stasis of blood that forms of blood; Yin deficiency affecting yang, the deficiency of yang is cold solidifying, also can cause sun in hemostasis.
Prior art is not applied lycopodium calvatum preparation and prevents and treats the health-caring biscuit of hyperglycaemia, and the single and health care of taste has its limitation.As invention---the Roselle biscuits that is 200610048632.0 at the number of patent application of Chinese patent information centre announcement, this invention is made through the common process of making biscuit by corn flour, buckwheat flour, flour, large bean flour, Roselle calyx powder, honey element, leavening agent and water, its health care has its advantage, but also has weak point.
Summary of the invention
The object of the invention is to provide a kind of health-caring biscuit of preventing and treating hyperglycaemia, to prevent people to cause disease because blood sugar raises, also play health care booster action for the treatment of the diabetes state of an illness.
Technical scheme: a kind of health-caring biscuit of preventing and treating hyperglycaemia, by preparing burden and form by weight below: lycopodium calvatum liquid extract 20, low powder 120, skimmed milk power 10, butter 40, xylitol 25; Described lycopodium calvatum liquid extract is made liquid extract by the composition of raw materials of following weight portion: lycopodium calvatum 10-20, frangipanis 8-20, Radix Glycyrrhizae 3-10, seed of Chinese dodder 5-10, Poria cocos 10-20, tuber of dwarf lilyturf 5-10.
Preparation method is: 1, lycopodium calvatum liquid extract and pure water are formed to biscuit water for subsequent use with the ratio of 1:2; 2, butter thermoplastic, adds xylitol to mix thoroughly, beats to cream pasty state with egg-whisk, then adds biscuit water for subsequent use, low powder and skimmed milk power to mix thoroughly; 3, batter is packed into piping bag and squeeze on baking tray, add a cover tinfoil.Baking box preheating 180 is spent, and roasting 20 minutes of middle level turns roasting about 10 minutes of 170 degree to drying.
As optimization, a kind of health-caring biscuit of preventing and treating hyperglycaemia of the present invention, by preparing burden and form by weight below: lycopodium calvatum liquid extract 20, low powder 120, skimmed milk power 10, butter 40, xylitol 25; Described lycopodium calvatum liquid extract is made liquid extract by the composition of raw materials of following weight portion: lycopodium calvatum 10-20, frangipanis 8-20, Radix Glycyrrhizae 3-10, seed of Chinese dodder 5-10, Poria cocos 10-20, tuber of dwarf lilyturf 5-10, rush 3-5, dark plum 3-10.
Lycopodium calvatum, toil temperature, expelling wind and clearing away cold, dehumidifying are subsided a swelling, are stimulated the circulation of the blood and cause the muscles and joints to relax." Hunan medicine will " records lycopodium calvatum: sweet, flat.Nontoxic, enter the heart, kidney two warps, relax the muscles and stimulate the blood circulation, invigorating qi and dredging collateral.
Frangipanis, cool in nature, taste is sweet, light; Return large intestine, stomach warp, there is effect of moistening lung removing toxic substances, clearing heat and expelling damp, laxation.
Radix Glycyrrhizae taste is sweet, flat.The thoughts of returning home, lung, spleen, stomach warp.Function cures mainly: invigorates the spleen and benefits qi, and clearing heat and detoxicating, expelling phlegm and arresting coughing, relieving spasm to stop pain, coordinating the drug actions of a prescription.For weakness of the spleen and the stomach, lassitude hypodynamia, palpitation, coughing with a lot of sputum, gastral cavity abdomen, the anxious pain of four limbs contraction, carbuncle sore tumefacting virus, cushion toxicity, strong.
Seed of Chinese dodder acrid-sweet flavor, property is flat, enters liver, kidney two warps.There is tonifying kidney and benefiting sperm, nourish the liver to improve visual acuity, antiabortive effect.
Poria cocos taste is sweet, light, property is flat, be used as medicine there is clearing damp and promoting diuresis, the function of beneficial spleen and stomach, antitoxic heart-soothing and sedative.Modern medicine study: Poria cocos energy enhanced machine body immunity function, pachymaran has significantly antitumor and protect the liver dirty effect.
The tuber of dwarf lilyturf, the micro-sugariness hardship of property, cold, there is nourishing Yin and moistening lung, reinforcing stomach reg fluid, the relieving restlessness that clears away heart-fire, reinforcing yin essence benefit essence, five viscera settling effect.
Rush, is slightly cold; Sweet, light; The thoughts of returning home; Lung; Small intestine; Urinary bladder channel.Effect: promoting diuresis for stranguria; Clearing heart fire.Dark plum acid, puckery, flat, returns liver, spleen, lung, large intestine channel.[function cures mainly] astringes the lung, and puckery intestines, promote the production of body fluid, claming ascaris.For chronic cough of deficiency lung, protracted dysentery laxation, abnormal heat is quenched one's thirst, ascariasis of biliary tract vomiting stomachache, ascariasis of biliary tract (" Chinese pharmacopoeia ").
Advantage of the present invention: 1, lycopodium calvatum Xin Wenyi impairment of yin blood of the present invention, therefore adapted frangipanis, Radix Glycyrrhizae are in harmonious proportion, make its institute partially, its taste is glycol, fresh and sweet, has channels sootheing and network vessel quickening, function of promoting blood circulation to disperse blood clots.
2, taste glycol of the present invention is pure and fresh, has increased the novel taste of health-caring biscuit.Seed of Chinese dodder tonifying kidney and benefiting sperm, Poria cocos clearing damp and promoting diuresis, beneficial spleen and stomach, the tuber of dwarf lilyturf is nourishing Yin and moistening lung, reinforcing stomach reg fluid, the relieving restlessness that clears away heart-fire, and rush clearing heart fire, dark plum are quenched one's thirst and are brought down a fever, and more contribute to promoting blood circulation and removing blood stasis hypoglycemic.
3, the present invention is by the balance of frangipanis, the seed of Chinese dodder, Poria cocos, the tuber of dwarf lilyturf, rush conditioning human body-centered liver spleen lung kidney the five internal organs, and stagnation resolvation is pure and impure quenches one's thirst, and relax the muscles and stimulate the blood circulation again, thereby invigorating qi and dredging collateral reaches hypoglycemic object with lycopodium calvatum.
4, Chinese medicine powder of the present invention has significant hypoglycemic activity to adrenaline hyperglycaemia mouse and alloxan hyperglycemia mouse.Each 20 of male and female mice is selected in experiment; Adopt respectively adrenaline and alloxan to set up hyperglycaemia mouse model, then give Chinese medicine powder of the present invention, glibenclamide, insoral and treat and survey blood sugar level.In the hyperglycemia mouse of bringing out at adrenaline, Chinese medicine powder of the present invention can make fasting serum glucose [(16. 58 ± 3. 92) mmol/L] be reduced to (7. 56 ± 2. 63) mmol/L, effect and glibenclamide comparison, no significant difference (P>0.05); In the hyperglycemia mouse of model induced by alloxan, the present invention is reduced to fasting serum glucose [(15. 56 ± 1. 83) mmol/L] (7. 55 ± 1.65) mmol/L, blood sugar reducing function is significantly better than insoral (P<0 05), and causes hypoglycemic side effect without glibenclamide.Conclusion: the present invention can significantly reduce the blood sugar level (P <0. 001) of 2 kinds of modeling animals, and makes blood sugar be down to normal level.
5, Chinese medicine powder of the present invention shows through more than the 60 routine sugared dung patients' that make a definite diagnosis clinical observation on the therapeutic effect, and the present invention has remarkable reduction glycosuria patient's blood sugar level, makes blood sugar recovery normal.
Clinical observation result of the present invention:
1.1 physical data: select the People's Hospital of city outpatient service diabetes B patient 60 examples, be divided at random two groups.Treatment group 30 examples, male 16 examples, female's 14 examples, 30～70 years old age, average (50 ± 1.5) year, the course of disease 6 months～15 years, average (8.0 ± 1.2) year; Control group 30 examples, male 18 examples, female's 12 examples, 29～70 years old age.Two groups of physical data comparing difference not statistically significants (P>0.05), have comparativity.
1.2 case selections: with reference to the World Health Organization's (WHO) diabetes diagnosis in 1999 and somatotype standard [1]: diabetic symptom+random time plasma glucose levels >=11.1mmol/L(200mg/dl).The patient's random packet that meets above-mentioned standard is carried out to observational study, and the patient that part takes traditional Chinese medicine stops former Chinese medicine and includes observation in after 2 weeks, and the patient's to be directly brought into not taking traditional Chinese medicine is observed.Two groups of patients all give diabetes Primary Care, comprise diet control, kinesiatrics and orally-taken blood sugar reducing Western medicine, and hypoglycemic Western medicine adopts melbine, carries out drug usage and dose adjustment according to blood sugar situation.
1.3 methods of treatments: treatment group is taken Chinese medicine powder of the present invention on the basis of taking melbine.Basic side is made up of the composition of raw materials of following weight portion: lycopodium calvatum 10, frangipanis 10, Radix Glycyrrhizae 3, the seed of Chinese dodder 5, Poria cocos 10, the tuber of dwarf lilyturf 5; Every natural gift are taken for three times, each 4 grams.Control group routine is taken melbine.Two groups are consistent in diet control, kinesiatrics, and be 2 months two groups of courses for the treatment of.
1.4 observation index: measure respectively fasting blood-glucose (FPG), postprandial blood sugar (2hBG), glycosylated hemoglobin (HbA1c), FPI (FINS), blood fat (TC, TG, HDL-C, LDL-C) before and after treatment, blood sugar determination of glucose oxidase, insulin is measured with putting the method for exempting from, blood fat is measured with automatic clinical chemistry analyzer, HOMA-IR employing Haffner etc. [3,4] in Homa model, calculate the formula of IR, be HOMA-IR=FPG × FINS/22.5 (FPG unit is mmol/L, and FINS unit is mU/L).
1.5 statistical methods: adopt SPSS 14.0 statistical analysis softwares to carry out statistical procedures.Measurement data adopts t inspection, enumeration data chi-square criterion.
2 results: before and after two groups of treatments, the variation of FPG, 2hBG, HbAIc, FINS and HOMA-IR refers to table 1.By in table 1, we can see, treat front two groups of patient FPG, 2hBG, HbAlc, FINS, the horizontal comparing difference not statistically significant of HOMA-IR (P>0.05); After treating, two groups of FPG, 2hBG, HbAlc, FINS, HOMA-IR levels have statistical significance (P<0.05 or P<0.01) with the front comparing differences for the treatment of, before treatment group patient's These parameters and treatment, relatively have significant difference (P<0.01).Prompting treatment group and control group all can reduce diabetes blood sugar, but it is more obvious to improve blood sugar with treatment group.
The variation of FPG, 2hBG, HbAlc, FINS and HOMA-IR before and after table 1 liang group patient treatment
Note: indices is compared with before treatment: * P<0.05, * * P<0.01; The rear two groups of FINS for the treatment of and HOMA-IR compare ^P<0.05, ^^P<0.01.
Before and after two groups of patient treatments, the variation of TC, TG, HDL-C, LDL-C is in table 2.From table 2, we can see the front two groups of patients' for the treatment of the horizontal comparing difference not statistically significant of TC, TG, HDL-C, LDL-C (P>0.05); After treatment, TC, TG, HDL-C, the LDL-C level of two groups have significant change, wherein TC, TG, LDL-C level have statistical significance (P<0.05) with the front comparing difference for the treatment of, and relatively have significant difference (P<0.01) before treatment group HDL-C level and treatment.Illustrate that treatment group and control group all can improve diabetic's blood lipid level, and more remarkable with treatment group effect.
The variation of TC, TG, HDL-C, the horizontal content of LDL-C before and after table 2 liang group patient treatment
Note: indices is compared with before treatment: * P<0.05, * * P<0.01; After treatment, two groups of indices are compared ^P<0.05, ^^P<0.01.
Detailed description of the invention
Embodiment 1: a kind of health-caring biscuit of preventing and treating hyperglycaemia, by preparing burden and form by weight below: lycopodium calvatum liquid extract 20, low powder 120, skimmed milk power 10, butter 40, xylitol 25; Described lycopodium calvatum liquid extract is made liquid extract by the composition of raw materials of following weight portion: lycopodium calvatum 10-20, frangipanis 8-20, Radix Glycyrrhizae 3-10, seed of Chinese dodder 5-10, Poria cocos 10-20, tuber of dwarf lilyturf 5-10.
Preparation method is: 1, lycopodium calvatum liquid extract and pure water are formed to biscuit water for subsequent use with the ratio of 1:2; 2, butter thermoplastic, adds xylitol to mix thoroughly, beats to cream pasty state with egg-whisk, then adds biscuit water for subsequent use, low powder and skimmed milk power to mix thoroughly; 3, batter is packed into piping bag and squeeze on baking tray, add a cover tinfoil.Baking box preheating 180 is spent, and roasting 20 minutes of middle level turns roasting about 10 minutes of 170 degree to drying.
Embodiment 2: a kind of health-caring biscuit of preventing and treating hyperglycaemia, by preparing burden and form by weight below: lycopodium calvatum liquid extract 20, low powder 120, skimmed milk power 10, butter 40, xylitol 25; Described lycopodium calvatum liquid extract is made liquid extract by the composition of raw materials of following weight portion: lycopodium calvatum 10-20, frangipanis 8-20, Radix Glycyrrhizae 3-10, seed of Chinese dodder 5-10, Poria cocos 10-20, tuber of dwarf lilyturf 5-10, rush 3-5, dark plum 3-10.
Preparation method is with embodiment 1.
Claims (2)
1. prevent and treat a health-caring biscuit for hyperglycaemia, it is characterized in that by preparing burden and form by weight below: lycopodium calvatum liquid extract 20, low powder 120, skimmed milk power 10, butter 40, xylitol 25; Described lycopodium calvatum liquid extract is made liquid extract by the composition of raw materials of following weight portion: lycopodium calvatum 10-20, frangipanis 8-20, Radix Glycyrrhizae 3-10, seed of Chinese dodder 5-10, Poria cocos 10-20, tuber of dwarf lilyturf 5-10.
2. prevent and treat a health-caring biscuit for hyperglycaemia, it is characterized in that by preparing burden and form by weight below: lycopodium calvatum liquid extract 20, low powder 120, skimmed milk power 10, butter 40, xylitol 25; Described lycopodium calvatum liquid extract is made liquid extract by the composition of raw materials of following weight portion: lycopodium calvatum 10-20, frangipanis 8-20, Radix Glycyrrhizae 3-10, seed of Chinese dodder 5-10, Poria cocos 10-20, tuber of dwarf lilyturf 5-10, rush 3-5, dark plum 3-10.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410179957.7A CN103907661A (en) | 2014-04-30 | 2014-04-30 | Health care biscuit capable of preventing hyperglycemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410179957.7A CN103907661A (en) | 2014-04-30 | 2014-04-30 | Health care biscuit capable of preventing hyperglycemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103907661A true CN103907661A (en) | 2014-07-09 |
Family
ID=51033934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410179957.7A Pending CN103907661A (en) | 2014-04-30 | 2014-04-30 | Health care biscuit capable of preventing hyperglycemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103907661A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104489034A (en) * | 2014-12-23 | 2015-04-08 | 胡丽萍 | Health care biscuit with tumor preventing and treating function |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090047397A1 (en) * | 2007-07-16 | 2009-02-19 | Tang Jill S | Composition and Method of Preparing Ready-to-Eat Cereal with Konjac Flour as a Main Ingredient |
| CN102613271A (en) * | 2012-03-28 | 2012-08-01 | 常熟市玉山食品有限公司 | Fruit and vegetable health biscuit capable of reducing blood sugar and blood lipid |
| CN102919331A (en) * | 2012-11-29 | 2013-02-13 | 胡丽萍 | Health-care biscuit for preventing and treating hyperlipidemia |
| CN102940268A (en) * | 2012-11-29 | 2013-02-27 | 陈花娇 | Chicken sausage |
| CN103098841A (en) * | 2011-11-12 | 2013-05-15 | 郭志惠 | Manufacture method for sugar-free nutritious digestion biscuit |
| CN103719202A (en) * | 2012-10-14 | 2014-04-16 | 青岛医防消毒专业技术中心 | Biscuit for dietary therapy of diabetes and fatty liver |
-
2014
- 2014-04-30 CN CN201410179957.7A patent/CN103907661A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090047397A1 (en) * | 2007-07-16 | 2009-02-19 | Tang Jill S | Composition and Method of Preparing Ready-to-Eat Cereal with Konjac Flour as a Main Ingredient |
| CN103098841A (en) * | 2011-11-12 | 2013-05-15 | 郭志惠 | Manufacture method for sugar-free nutritious digestion biscuit |
| CN102613271A (en) * | 2012-03-28 | 2012-08-01 | 常熟市玉山食品有限公司 | Fruit and vegetable health biscuit capable of reducing blood sugar and blood lipid |
| CN103719202A (en) * | 2012-10-14 | 2014-04-16 | 青岛医防消毒专业技术中心 | Biscuit for dietary therapy of diabetes and fatty liver |
| CN102919331A (en) * | 2012-11-29 | 2013-02-13 | 胡丽萍 | Health-care biscuit for preventing and treating hyperlipidemia |
| CN102940268A (en) * | 2012-11-29 | 2013-02-27 | 陈花娇 | Chicken sausage |
Non-Patent Citations (2)
| Title |
|---|
| 成海艳: "《高血脂家庭保健与食疗》", 31 January 2009, article "高血脂与糖尿病", pages: 11-12 * |
| 朱朝阳: "《糖尿病防治指南》", 31 March 2013, article "高血脂与糖尿病有什么关系", pages: 39-40 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104489034A (en) * | 2014-12-23 | 2015-04-08 | 胡丽萍 | Health care biscuit with tumor preventing and treating function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105901260A (en) | Donkey-hide gelatin preserved plum and preparation method thereof | |
| CN103919022A (en) | Health-care steamed buns for preventing and treating hyperglycemia | |
| CN103919153A (en) | Healthcare quail sausage | |
| CN103919176A (en) | Lobster meat sausage | |
| CN103907957A (en) | Bamboo rat sausage | |
| CN103947925A (en) | Buckwheat porridge | |
| CN103947916A (en) | Jelly | |
| CN103919162A (en) | Mutton sausage | |
| CN103919175A (en) | Prawn sausage | |
| CN103919155A (en) | Healthcare pigeon sausage | |
| CN103907970A (en) | Whitebait meat balls | |
| CN103932226A (en) | Venison sausage | |
| CN103931772A (en) | Milk tea | |
| CN103918740A (en) | Premixed powder for preventing and treating hyperglycemia | |
| CN103907963A (en) | Crocodile meat sausage | |
| CN103907956A (en) | Health horsemeat sausage | |
| CN103911266A (en) | Yellow wine | |
| CN103907952A (en) | Health-care ostrich meat sausage | |
| CN103907658A (en) | Healthy bread for prevention and treatment of high blood sugar | |
| CN103907951A (en) | Health-care duck meat sausage | |
| CN103907824A (en) | Health-care noodles capable of preventing and treating hyperglycemia | |
| CN103911267A (en) | White spirit | |
| CN103919154A (en) | Health-care chicken sausage | |
| CN103919163A (en) | Ass meat sausage | |
| CN103919161A (en) | Healthcare pork sausage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140709 |
|
| WD01 | Invention patent application deemed withdrawn after publication |